As economy develops and living standards improve, Chinese people’s dietary pattern changes, resulting in excess heat. Meanwhile, the drop in physical activities leads to the increased obesity rate. Other factors like the ageing population also play a role in the rapid increase of diabetes incidence in China.
Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, was developed by Novo Nordisk in 2008 to treat diabetes. Liraglutide, a derivative attained by attaching a fatty acid molecule to GLP-1 molecule, can reduce the HbA1c level and weight of type 2 diabetes mellitus (T2DM) patients and improve the function of beta cells. Since it stimulates insulin secretion and inhibits glucagon secretion only when blood glucose levels are higher than normal, it shows negligible risk of hypoglycemia. On Jan. 25, 2010, liraglutide was approved by FDA to be used as the second-line drug alone or together with other oral antidiabetic drugs for the treatment of T2DM. In 2013, the sales value of liraglutide around the world exceeded USD 2 billion.
After entering China in Oct. 2011, liraglutide develops fast with annual sales value rising from less than CNY 0.5 million in 2011 to CNY 19.71 million in 2014 and CAGR reaching up to 246% during the period of 2011-2013. Currently, liraglutide market in China is monopolized by Novo Nordisk. Although liraglutide, as an imported drug, is priced relatively high in China, it still has good market prospects.
Readers can get at least the following information from this report:
-market size of liraglutide in China
-price of liraglutide in Chinese market
-share of dosage forms of liraglutide in China
-market outlook of liraglutide in China
The author suggests the following groups of people purchase this report:
-manufacturers of anti-diabetic drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service